News
-
-
PRESS RELEASE
Edison issues review on BB Biotech (BION): A recovering sector with a healthy prognosis
Edison issues review on BB Biotech (BION), highlighting its performance improvement and optimistic outlook in the recovering biotech sector, offering investors an opportunity for acquisition at an attractive level -
-
-
-
PRESS RELEASE
BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates
BB Biotech reports solid first-quarter results as interest rates impact biotech stock market. Net profit reaches CHF 260 mn. Key portfolio adjustments and milestones highlighted -
-
-
-
![Accesswire](/assets/images/accesswire-inline.png)
-
APWG 2024 Cybercrime Research Conference Extends Submission Deadline to July 7
-
Product Creation Studio Partners With PatchClamp Medtech Inc. to Develop Revolutionary Dural Repair System
-
XS Financial Enters Into Definitive Agreement to Be Taken Private
-
TRU Engages Investor Relations Specialists HE Capital Markets
-
DuJour Media Jason Binn Celebrates Successful 12th Anniversary Cover Party with Star-Studded After-Party and Record Turnout
![EQS Group](/assets/images/eqs-group.png)
-
Just – Evotec Biologics selected by U.S. Department of Defense for Manufacturing Optimization Program
-
HORNBACH Group delivers strong Q1 2024/25 results increasing earnings per share y-o-y by 44% – full-year outlook confirmed unchanged
-
Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 Study Outcomes in Spine, Indicating Superiority Over Autograft
-
Meyer Burger makes significant progress in relocating its core business to the USA
-
BIRKENSTOCK ANNOUNCES LAUNCH OF SECONDARY OFFERING
![Les Echos](/assets/images/les-echos.png)
-
Signing of the share purchase agreement for the acquisition of a majority stake in Neoen by Brookfield from Impala and other shareholders and of a tender agreement between Brookfield and Bpifrance
-
Schneider Electric launches an offering of bonds convertible into new shares and/or exchangeable for existing shares (OCEANEs) due 2031 for a nominal amount of €750 million and a concurrent repurchase of its outstanding OCEANEs due 2026
-
Gimv increases its stake in TINC – Gimv and Belfius conclude agreement in principle on the sale of the shares of Belfius Insurance in TINC
-
Disclosure of Share Capital and Voting Rights Outstanding as of May 31, 2024
-
2023/2024 Third Quarter Sales